News

Strensiq (asfotase alfa), a bone-targeted enzyme replacement therapy, is the first such treatment to be approved in Japan for HPP patients. The company intends to start commercial treatment

The deal amount was paid by Cardinal to Court Square Capital Partners using existing cash and new debt following the receipt of regulatory approvals and satisfying other customary

Horizon’s proposal represents a premium of 42 percent to the closing price of Depomed on July 6, 2015. The transaction, if consummated, would be immediately and substantially accretive

The agreement will offer an additional source of the dolutegravir active pharmaceutical ingredient (API), and will allow ViiV Healthcare to offer a competitive supply of the finished product

The instrument will be based on Milestone Scientific’s painless, computer-controlled injection and drug delivery technology, which has commercial applications across a broad spectrum of medical and dental procedures.

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The

Narcan was the first naloxone product approved by the U.S. Food and Drug Administration (FDA) as a treatment for opioid overdose in 1971. Narcan has not been distributed

The trial is a follow-on study to a first Phase I/IIa study completed in 2014, enrolling 26 patients. Functioning as their own placebo, all patients were subjected to

As part of the deal, Glycotope will be Cantargia’s production partner to obtain material for the clinical studies of CAN04 in cancer patients. The deal will also see